Irbesartan/Hct Stada (Hydrochlorothiazide, Irbesartan)

• Irbesartan/Hydrochlorothiazide acts on the renin‑angiotensin‑aldosterone system to control elevated blood pressure.
• Essential hypertension: reduces systolic and diastolic pressure in patients with primary hypertension.
• Secondary hypertension: assists in blood pressure control when hypertension is due to identifiable causes.
• Hypertension with fluid retention: combines vasodilation and diuresis to manage blood pressure and excess fluid.
• High cardiovascular risk patients: contributes to overall risk reduction when added to standard therapy.

• Irbesartan selectively blocks angiotensin II type 1 (AT₁) receptors, preventing angiotensin‑II‑mediated vasoconstriction and aldosterone release, which lowers systemic vascular resistance. Hydrochlorothiazide inhibits the Na⁺/Cl⁻ cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption and promoting diuresis. This dual mechanism allows for effective control of hypertension with a lower dose of each component, improving tolerability.

Irbesartan/Hydrochlorothiazide may be associated with a range of adverse reactions, which are classified by frequency.

Common Side Effects

• Dizziness: light‑headed sensation, especially after the first dose.
• Headache: mild to moderate head pain.
• Fatigue: feeling of tiredness or reduced energy.
• Increased urination: due to the diuretic effect.

Serious or Rare Side Effects

• Hyperkalemia: elevated potassium levels that may cause cardiac arrhythmia.
• Acute kidney injury: sudden decline in renal function, indicated by rising creatinine.
• Severe allergic reaction: rash, swelling, or difficulty breathing (anaphylaxis).

• Before prescribing Irbesartan/Hydrochlorothiazide, clinicians should evaluate several safety considerations.
• Renal function: assess baseline kidney function and monitor serum creatinine.
• Electrolytes: check potassium and sodium levels, especially in patients on other diuretics.
• Pregnancy: avoid use during pregnancy due to potential fetal toxicity.
• Concomitant drugs: review use of potassium‑sparing agents or NSAIDs that may affect renal handling.
• Elderly patients: start with lower doses and monitor for orthostatic hypotension.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Irbesartan/Hydrochlorothiazide can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• ACE inhibitors or other ARBs: combined use may increase risk of hyperkalemia and renal impairment.
• Lithium: concomitant use can raise lithium levels, leading to toxicity.
• NSAIDs: may reduce antihypertensive effect and worsen kidney function.

Moderate Interactions (Monitor Closely)

• Potassium‑sparing diuretics: may cause additive hyperkalemia.
• Antidiabetic drugs: thiazide component can increase blood glucose, requiring dose adjustment.
• CYP2C9 inhibitors (e.g., fluconazole): may raise irbesartan concentrations.